Rapid production of recombinant human IgG with improved ADCC effector function in a transient expression system

Biotechnology and Bioengineering

Volumn 105, Issue 2, 2010, Pages 350-357

  Van Berkel, Patrick H C ^a   Gerritsen, Jolanda ^a   Van Voskuilen, Edwin ^a   Perdok, Gerrard ^a   Vink, Tom ^a   Van De Winkel, Jan G J ^a   Parren, Paul W H I ^a  

^a GENMAB   (Netherlands)

Author keywords

ADCC; Fc RIIIA; Human IgG; Kifunensine

Indexed keywords

EFFECTOR CELLS; ELISA-BASED ASSAYS; GLYCANS; GLYCOSIDASE INHIBITORS; HEK-293; HUMAN IGG; KIFUNENSINE; N-LINKED GLYCOSYLATION; OLIGOMANNOSE; PERIPHERAL BLOOD; TRANSIENT EXPRESSION;

CELL DEATH;

CD16 ANTIGEN; FUCOSE; GLYCAN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; KIFUNENSINE; MANNOSE OLIGOSACCHARIDE;

ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BINDING AFFINITY; CELL STRAIN HEK293; CONTROLLED STUDY; EFFECTOR CELL; ENDOPLASMIC RETICULUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSYLATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMID; TRANSIENT EXPRESSION;

ALKALOIDS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BIOTECHNOLOGY; CELL LINE; GENE EXPRESSION; GLYCOSIDE HYDROLASES; HUMANS; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR; PLASMIDS; RECEPTORS, IGG; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 74849136016     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.22535     Document Type: Article

References (22)

1. Boyd PN, Lines AC, Patel AK. 1995. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol 32:1311-1318.
2. Davies J, Jiang L, Pan L, LaBarreMJ, Anderson D, Reff M. 2001. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FCgRIII. Biotechnol Bioeng 74:288-294.
3. Ferrara C, Stuart F, Sondermann P, Brunker P, Umana P. 2006. The Carbohydrate at FcgRIIIa Asn-162: An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 281:5032-5036.
4. Hodoniczky J, Zheng YZ, James DC. 2005. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 21:1644-1652.
5. Jefferis R. 2001. Glycosylation of human IgG. Relevance to therapeutic applications. Biopharm, September, 19-27.
6. Jefferis R. 2005. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 21:11-16.
7. Kanda Y, Yamane-Ohnuki N, Sakai N, Yamano K, Nakano R, Inoue M, Misaka H, Iida S, Wakitani M, Konno Y, Yano K, Shitara K, Hosoi S, Satoh M. 2006. Comparison of cell lines for stable production of fucosenegative antibodies with enhanced ADCC. Biotechnol Bioeng 94:680-688.
8. Kaneko Y, Nimmerjahn F, Ravetch JV. 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313:670-673.
9. Peipp M, Lammerts van Bueren JJ, Schneider-Merck T, Bleeker WWK, Dechant M, Beyer T, Repp R, van Berkel PHC, Vink T, van de Winkel JGJ, et al. 2008. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 112:2390-2399.
10. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. 2005. Monoclonal antibody successes in the clinic. Nat Biotech 23:1073-1078.
11. Scallon B, McCarthy S, Radewonuk J, Cai A, Naso M, Raju TS, Capocasale R. 2007a. Quantitative in vivo comparisons of the Fc[gamma] receptordependent agonist activities of different fucosylation variants of an immunoglobulin G antibody. Inter Immunopharmacol 7:761-772.
12. Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS. 2007b. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 44:1524-1534.
13. Schuster M, Umana P, Ferrara C, Brunker P, Gerdes C, Waxenecker G, WiederkumS, Schwager C, Loibner H, HimmlerG, et al. 2005. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. Cancer Res 65:7934-7941.
14. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcgRIII and antibody-dependent cellular toxicity. J Biol Chem 277:26733-26740.
15. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, et al. 2003. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278:3466-3473.
16. Tsuchiya N, Endo T, Matsuta K, Yoshinoya S, Aikawa T, Kosuge E, Takeuchi F, Miyamoto T, Kobata A. 1989. Effects of galactose depletion from oligosaccharide chains on immunological activities of human IgG. J Rheumatol 16:285-290.
17. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. 1999. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibodydependent cellular cytotoxicity activity. Nat Biotech 17:176-180.
18. van Berkel PHC, Gerritsen J, Perdok G, Valbjørn J, Vink T, van de Winkel JGJ, Parren PWHI. 2009. N-linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG. Biotechnol Prog 25:244-251.
19. Wright A, Morrison SL. 1998. Effect of C2-associated carbohydrate structure on Ig effector function: Studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J Immunol 160(7):3393-3402.
20. Wright A, Sato Y, Okada T, Chang KH, Endo T, Morrison SL. 2000. In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure. Glycobiology 10:1347-1355.
21. Zhou Q, Shankara S, Roy A, Qiu H, Estes S, McVie-Wylie A, Culm-Merdek K, Park A, Pan C, Edmunds T. 2008. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng 99:652-665.
22. Zhu L, van de Lavoir M-C, Albanese J, Beenhouwer DO, Cardarelli PM, Cuison S, Deng DF, Deshpande S, Diamond JH, Green L, et al. 2005. Production of humanmonoclonal antibody in eggs of chimeric chickens. Nat Biotech 23:1159-1169.